Mengke Pharmaceutical announced that Best Idea International Limited, a shareholder holding 5% or more of the shares, reduced its holdings of the company's shares by 6.5561 million shares through centralized bidding transactions between October 9, 2025 and January 6, 2026. The shareholding ratio was reduced from 8.91% to 7.91%, and changes in equity hit the 1% mark. This change in equity is due to the shareholders' implementation of the disclosed share reduction plan. It does not involve funding sources, etc., and will not cause changes in the company's controlling shareholders or actual controllers, nor has it had a significant impact on the company's governance structure and ability to continue operating.

Mengke Pharmaceutical announced that Best Idea International Limited, a shareholder holding 5% or more of the shares, reduced its holdings of the company's shares by 6.5561 million shares through centralized bidding transactions between October 9, 2025 and January 6, 2026. The shareholding ratio was reduced from 8.91% to 7.91%, and changes in equity hit the 1% mark. This change in equity is due to the shareholders' implementation of the disclosed share reduction plan. It does not involve funding sources, etc., and will not cause changes in the company's controlling shareholders or actual controllers, nor has it had a significant impact on the company's governance structure and ability to continue operating.